ANNAPOLIS, Md., Jan. 10, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present ...
Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.The Master Account of the fund returned 2.6% ...
Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO ...
ANNAPOLIS, Md., Jan. 10, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at ...
Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. The Master Account of the fund returned 2.6% net in the fourth quarter compared to 2.4% ...
Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. The Master Account of the fund returned 2.6 ...
Alphyn Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. The Master Account of the fund returned 2.6% ...